JP2022548050A5 - - Google Patents
Info
- Publication number
- JP2022548050A5 JP2022548050A5 JP2022516126A JP2022516126A JP2022548050A5 JP 2022548050 A5 JP2022548050 A5 JP 2022548050A5 JP 2022516126 A JP2022516126 A JP 2022516126A JP 2022516126 A JP2022516126 A JP 2022516126A JP 2022548050 A5 JP2022548050 A5 JP 2022548050A5
- Authority
- JP
- Japan
- Prior art keywords
- gnrh
- seq
- oligomer
- peptide
- amino acid
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2025076282A JP2025124645A (ja) | 2019-09-12 | 2025-05-01 | 前立腺癌処置のための免疫治療薬 |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962899553P | 2019-09-12 | 2019-09-12 | |
| US62/899,553 | 2019-09-12 | ||
| PCT/US2020/050194 WO2021050722A1 (en) | 2019-09-12 | 2020-09-10 | An immunotherapeutic for prostate cancer treatment |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2025076282A Division JP2025124645A (ja) | 2019-09-12 | 2025-05-01 | 前立腺癌処置のための免疫治療薬 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2022548050A JP2022548050A (ja) | 2022-11-16 |
| JP2022548050A5 true JP2022548050A5 (https=) | 2023-09-14 |
| JP7677953B2 JP7677953B2 (ja) | 2025-05-15 |
Family
ID=74867215
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022516126A Active JP7677953B2 (ja) | 2019-09-12 | 2020-09-10 | 前立腺癌処置のための免疫治療薬 |
| JP2025076282A Pending JP2025124645A (ja) | 2019-09-12 | 2025-05-01 | 前立腺癌処置のための免疫治療薬 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2025076282A Pending JP2025124645A (ja) | 2019-09-12 | 2025-05-01 | 前立腺癌処置のための免疫治療薬 |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US20220339238A1 (https=) |
| EP (2) | EP4028043A4 (https=) |
| JP (2) | JP7677953B2 (https=) |
| KR (1) | KR20220062080A (https=) |
| CN (1) | CN114599387A (https=) |
| AU (1) | AU2020346818A1 (https=) |
| BR (1) | BR112022004477A2 (https=) |
| CA (1) | CA3152055A1 (https=) |
| MX (1) | MX2022003100A (https=) |
| WO (1) | WO2021050722A1 (https=) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP7677953B2 (ja) * | 2019-09-12 | 2025-05-15 | ヘキサマー・セラピューティクス・インコーポレイテッド | 前立腺癌処置のための免疫治療薬 |
| US20230346920A1 (en) * | 2020-05-04 | 2023-11-02 | Hexamer Therapeutics, Inc. | Vaccines against viral pathogens |
| CN118684781A (zh) * | 2023-03-21 | 2024-09-24 | 深圳赫兹生命科学技术有限公司 | GnRH-VLP重组去势疫苗及其制备方法 |
| JP7837616B2 (ja) * | 2025-07-25 | 2026-03-31 | 株式会社大都技研 | 遊技台 |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5723129A (en) * | 1991-10-16 | 1998-03-03 | University Of Saskatchewan | GnRH-leukotoxin chimeras |
| WO1997015316A1 (en) * | 1995-10-27 | 1997-05-01 | Merck & Co., Inc. | Conjugates of gonadotropin releasing hormone |
| US6319503B1 (en) * | 1998-02-19 | 2001-11-20 | Proteinix Company | Heat shock fusion-based vaccine system |
| CU23204A1 (es) * | 2002-12-27 | 2007-05-18 | Ct Ingenieria Genetica Biotech | Combinaciones de factores reguladores del crecimiento y hormonas para el tratamiento de neoplasias |
| CU23739A1 (es) * | 2008-09-30 | 2011-12-28 | Ct Ingenieria Genetica Biotech | Composición farmacéutica utilizando combinaciones de variantes de la hormona liberadora de las gonadotropinas (gnrh) como inmunógeno |
| WO2015164798A1 (en) * | 2014-04-25 | 2015-10-29 | Tria Bioscience Corp. | Synthetic hapten carrier compositions and methods |
| AU2016419048B2 (en) * | 2016-08-11 | 2024-02-15 | The Council Of The Queensland Institute Of Medical Research | Immune-modulating compounds |
| MA52591A (fr) * | 2018-07-12 | 2021-06-02 | Hexamer Therapeutics Inc | Échafaudage peptidique autoassemblé |
| JP7677953B2 (ja) * | 2019-09-12 | 2025-05-15 | ヘキサマー・セラピューティクス・インコーポレイテッド | 前立腺癌処置のための免疫治療薬 |
| US20230346920A1 (en) * | 2020-05-04 | 2023-11-02 | Hexamer Therapeutics, Inc. | Vaccines against viral pathogens |
-
2020
- 2020-09-10 JP JP2022516126A patent/JP7677953B2/ja active Active
- 2020-09-10 CA CA3152055A patent/CA3152055A1/en active Pending
- 2020-09-10 US US17/753,663 patent/US20220339238A1/en active Pending
- 2020-09-10 WO PCT/US2020/050194 patent/WO2021050722A1/en not_active Ceased
- 2020-09-10 EP EP20863353.7A patent/EP4028043A4/en active Pending
- 2020-09-10 AU AU2020346818A patent/AU2020346818A1/en active Pending
- 2020-09-10 CN CN202080062776.XA patent/CN114599387A/zh active Pending
- 2020-09-10 BR BR112022004477A patent/BR112022004477A2/pt unknown
- 2020-09-10 EP EP22203434.0A patent/EP4183417A1/en active Pending
- 2020-09-10 KR KR1020227012108A patent/KR20220062080A/ko active Pending
- 2020-09-10 MX MX2022003100A patent/MX2022003100A/es unknown
-
2025
- 2025-05-01 JP JP2025076282A patent/JP2025124645A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2022548050A5 (https=) | ||
| WJESMÜLLER et al. | Solid phase peptide synthesis of lipopeptide vaccines eliciting epitope‐specific B‐, T‐helper and T‐killer cell response | |
| ES2392080T3 (es) | Haces de hélices superenrolladas de lipopéptido y partículas pseudovíricas sintéticas | |
| FI3642340T3 (fi) | Muunneltu l-asparaginaasi | |
| JP2020528743A5 (https=) | ||
| DEFOORT et al. | A rational design of synthetic peptide vaccine with a built‐in adjuvant: A modular approach for unambiguity | |
| JP2018510215A5 (https=) | ||
| AR105817A1 (es) | Péptidos y combinaciones de péptidos para el uso en la inmunoterapia contra el cáncer de próstata y otros tipos de cáncer | |
| KR950700416A (ko) | 합성 헤모필루스 인플렌쟈 접합 백신 | |
| JP2004511528A (ja) | ワクチン組成物 | |
| US20030095979A1 (en) | Pharmaceutical preparations comprising modified peptides | |
| CA2375033A1 (en) | Vaccines against conformation-dependent antigens and against antigens that are not or are not only proteins or peptides | |
| US20030175285A1 (en) | Molecule of pharmaceutical interest comprising at its n-terminal a glutamic acid or a glutamine in the form of a physiologically acceptable strong acid | |
| PE20231506A1 (es) | Peptidos y combinaciones de peptidos para su uso en inmunoterapia contra una infeccion por sars-cov-2 (covid-19) | |
| JP2023541669A5 (https=) | ||
| AU610526B2 (en) | Improvements in or relating to hormones | |
| JP2023522198A5 (https=) | ||
| GB2220939B (en) | Peptide fragments of hiv and their use in vaccines and diagnosis | |
| WO1993003766A1 (en) | Multiple antigen peptides for use as hiv vaccines | |
| JP2021531337A5 (https=) | ||
| RU2011150283A (ru) | Пептиды ттк и вакцины, их содержащие | |
| RU2011140168A (ru) | Пептиды vangl1 и содержащие их вакцины | |
| WO2020014609A4 (en) | Self-assembling peptide scaffold | |
| RU2011130796A (ru) | Пептиды c1orf59 и содержащие их вакцины | |
| CN1625409B (zh) | 含可变肽表位的免疫原制剂及其制备方法 |